Filing Flows

Filing Flows › Health Care › Pro DEX (PDEX)

Pro DEX (PDEX) earnings and revenue breakdown

Latest: Q1 FY27 · 10-Q filed Oct 29, 2026 · Pro DEX (PDEX) Q1 FY27 earnings results →

Q1 FY27 Revenue up 11% year over year to $20.6M · 15¢ of every $1 of revenue kept as net profit · operating margin 17.1%

Pro DEX made $20.6M in Q1 FY27 (+11% Y/Y). Operating margin 17.1%, net earnings $3.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 29, 2026.

Revenue$20.6M
Year over year+11%
Operating margin17.1%
Net earnings$3.0M
Operating cash flow$6.5M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $20.6M in Q1 FY27, up 11% year over year and up 1% from the previous quarter.

Gross margin was 33.4%, up 4.4 points from Q1 FY26. Operating profit was $3.5M, a 17.1% margin (up 0.3 points year over year). Of the extra revenue versus Q1 FY26, 20% reached operating profit, above the 17% margin then. Operating expenses grew 48% against revenue growth of 11%. The fastest-growing cost line was Research & development (+58%). Net earnings were $3.0M, down 35% year over year. The effective tax rate was 9.8%.

Operating cash flow was $6.5M (up 181% year over year), 213% of net earnings. Non-cash charges added back $403K of depreciation and amortization and $135K of share-based compensation. Working capital and other items added $2.9M. Capital expenditures of $346K left free cash flow of $6.1M.

Quarterly history

Pro DEX revenue by quarterPro DEX revenue by quarter$17.4MQ3 FY25$17.5MQ4 FY25$18.5MQ1 FY26$18.7MQ2 FY26$19.9MQ3 FY26$20.4MQ4 FY26$20.6MQ1 FY27
Pro DEX net earnings by quarterPro DEX net earnings by quarter$3.3MQ3 FY25$1.2MQ4 FY25$4.7MQ1 FY26$2.2MQ2 FY26$3.9MQ3 FY26$2.9MQ4 FY26$3.0MQ1 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q1 FY2710-QOct 29, 2026$20.6M+11%17.1%$3.0M$6.5M
Q4 FY2610-KSep 3, 2026$20.4M+17%17.3%$2.9M−$273K
Q3 FY2610-QApr 30, 2026$19.9M+15%15.5%$3.9M$1.6M
Q2 FY2610-QJan 29, 2026$18.7M+11%17.5%$2.2M$3.6M
Q1 FY2610-QOct 30, 2025$18.5M+24%16.8%$4.7M$2.3M
Q4 FY2510-KSep 4, 2025$17.5M+16%7.7%$1.2M−$173K
Q3 FY2510-QMay 1, 2025$17.4M+22%20.9%$3.3M$754K

Charts

Pro DEX: revenue growth, year over year and quarter over quarterPro DEX: revenue growth, year over year and quarter over quarterY/YQ/Q+22%Q3 FY25+16%+0%Q4 FY25+24%+6%Q1 FY26+11%+1%Q2 FY26+15%+7%Q3 FY26+17%+2%Q4 FY26+11%+1%Q1 FY27
Latest (Q1 FY27): Y/Y +11%, Q/Q +1%.
Pro DEX: where the cash came from (+) and went (−), TTM to Q1 FY27Pro DEX: where the cash came from (+) and went (−), TTM to Q1 FY27Net borrowing (+) / repaid (−)−$13.1MOperating cash flow$11.4MCash drawn (+) / kept (−)−$11.2MOther financing$9.1MOther investing$4.4MCapital spending−$731KShares issued$102K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Pro DEX: profit against cash, quarter by quarterPro DEX: profit against cash, quarter by quarterNet incomeOperating cash flow$2.0M−$4.2MQ2 FY25$3.3M$754KQ3 FY25$1.2M−$173KQ4 FY25$4.7M$2.3MQ1 FY26$2.2M$3.6MQ2 FY26$3.9M$1.6MQ3 FY26$2.9M−$273KQ4 FY26$3.0M$6.5MQ1 FY27
Latest (Q1 FY27): Net income $3.0M, Operating cash flow $6.5M.
Pro DEX: diluted shares by fiscal yearPro DEX: diluted shares by fiscal year4MFY214MFY224MFY234MFY243MFY253MFY26
-15.7% since FY21: buybacks shrank the count.
Pro DEX: long-term debt falling due (FY26)Pro DEX: long-term debt falling due (FY26)$4.2M2027$3.6M2028$2.9M2029$2.2M2030$4.7M2031
Cash $8.2M, short-term investments $1.1M, long-term debt $17.5M at 2026-06-30.
Pro DEX in its industry: growth against margin (111 companies, SIC 3841)Pro DEX in its industry: growth against margin (111 companies, SIC 3841)revenue growth, year over year →↑ operating marginmedian +10%median -9%MDLNMMMSYKBSXBDXBAXSOLVRMDDXCMWSTMMEDPODDGMEDTFXICUIMMSIIARTPENHAETNDMEMBCIRTCATECGKOSOFIXINSPNVCRUFPTATRCBVSAORTPRCTTCMDARAYANGOKIDSSKINLMATHTFLMDXGCERSSIBNTMCISTIMINFUBBNXKMTSOSURANIKDCTHRCELSGHTIRMDXTNTLUNGNPCETELACARLLNSRSIMOBIAPYXSSIICVRXCLPTKRMDTLSIPROFSNWVCTSOIDXGUTMDRVPSNOAPREMNEPHDRIOVVOSBTCYNXGLMDAIMDNCPMINONE.SRTSSINTIVFNMTCNSPRAURXXAIRLUCDTNONINBSRNXTVTAKUSAQICUVYCOHRGNCNSYPLSEPETVFEMYOSRHCODXOBIORDGLPAVMGUTSPDEX (+11%, 17%)
Surgical & Medical Instruments & Apparatus; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Pro DEX

Pro-Dex, Inc. (“Company,” “Pro-Dex,” “we,” “our,” “us”) specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and craniomaxillofacial (“CMF”) markets. We have patented adaptive torque-limiting technology and proprietary sealing solutions that appeal to our customers, primarily medical device distributors. Additionally, we provide engineering, quality and regulatory consulting services to our customers. We also manufacture and sell rotary air motors to a wide range of industries; however, these motors comprise a de minimis portion of our business. Beginning in fiscal 2026, we began selling precision machined parts and assemblies for the aerospace and defense industries through our newly acquired subsidiary, Advanced Precision Machining, LLC (“APM”).

In its own words, from its annual report, filed Sep 3, 2026.

Pro DEX against its Surgical & Medical Instruments & Apparatus peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +11% against the peers' median +5%. Operating margin: 17.1% against the peers' median 15.9%.

CompanyQuarterRevenueY/YOp. margin
PDEX Pro DEXQ1 FY27$20.6M+11%17.1%
MDLN MedlineQ3 2026$7.9B+10%6.4%
MMM 3MQ3 2026$6.6B+1%23.7%
SYK StrykerQ3 2026$6.5B+8%15.9%
BSX Boston ScientificQ3 2026$5.1B+1%16.1%
BDX Becton DickinsonQ3 FY26$5.0B+5%13.3%
BAX Baxter InternationalQ3 2026$3.0B+5%7.6%
SOLV SolventumQ3 2026$1.9B-7%3.5%
RMD ResMedQ1 FY27$1.4B+6%32.0%

Source: Pro DEX 10-Q on SEC EDGAR · CIK 788920 · Surgical & Medical Instruments & Apparatus

13F: who owns PDEX and who is buying

Largest holders of PDEX (13F)Largest holders of PDEX (13F)BlackRock$9.0MVanguard Group$5.6MVanguard Capital Management LLC$4.8MDimensional Fund Advisors LP$3.3MPunch & Associates Investment Man…$3.1MGeode Capital Management, LLC$2.9MState Street$1.8MEllsworth Advisors, LLC$1.2MGoldman Sachs Group$1.1MPekin Hardy Strauss$966K
Funds' net buying of PDEX by quarter (13F)Funds' net buying of PDEX by quarter (13F)−$116K2024-09$1.6M2024-12$189K2025-03$3.5M2025-06−$575K2025-09−$768K2025-12$1.4M2026-03−$1.4M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on PDEX

History

Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results

Compare PDEX with

中文版：Pro DEX（PDEX）财报

Español · Français